Clinical Trial Update: To Assess the Effect of 336 Days Exposure of Paractin® on Pain & Disease Progression in Patients Suffering From Osteoarthritis of Knee Joint. [NA]

View source ↗

Summary

This clinical trial record notes the completion of a study evaluating 336 days of Paractin exposure on pain and disease progression in knee osteoarthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Knee Osteoarthritis

Drugs mentioned

• ParActin®

Snippet

Sponsor: Vedic Lifesciences Pvt. Ltd. | Conditions: Knee Osteoarthritis (Knee OA) | NA | Status: COMPLETED